Wedbush Securities Inc. decreased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,839 shares of the biopharmaceutical company’s stock after selling 7,312 shares during the quarter. Wedbush Securities Inc.’s holdings in Bristol-Myers Squibb were worth $3,054,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the stock. Delphi Private Advisors LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $108,000. Massey Quick Simon & CO. LLC increased its position in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the period. Horan Capital Advisors LLC. acquired a new position in Bristol-Myers Squibb during the third quarter worth approximately $122,000. NuWave Investment Management LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth approximately $119,000. Finally, Atlantic Trust LLC acquired a new position in Bristol-Myers Squibb during the second quarter worth approximately $111,000. Hedge funds and other institutional investors own 71.49% of the company’s stock.
Several research analysts have commented on BMY shares. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price target on the stock. in a research report on Thursday, December 28th. Morgan Stanley raised Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $51.56 to $78.00 in a research report on Thursday, February 15th. BMO Capital Markets reaffirmed a “sell” rating and set a $52.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, January 22nd. Finally, Leerink Swann lifted their price target on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $66.68.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.22 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 271.19%.
WARNING: “Bristol-Myers Squibb Co (BMY) Position Trimmed by Wedbush Securities Inc.” was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3295452/bristol-myers-squibb-co-bmy-position-trimmed-by-wedbush-securities-inc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.